Builder Shinetec has argued $48 million paid to the developer of a $185 million project in Sydney by Bank of China under a standby letter of credit was money it lent to the collapsed developer, with a judge seeming to agree the sum would otherwise be a windfall.
Canberra builder Geocon has brought a lawsuit against the developers of the Aspen and Establishment apartment buildings in Canberra, claiming it is owed $4 million in construction payments.
A judge has declined a creditor’s bid to wind up Victorian builder Roberts Construction Group, finding that the application relied on a “very modest” debt and involved a solicitor’s email “cast in threatening terms”.
The developers of an industrial-chic Melbourne apartment building have won a fight against the building’s owners corporation over a lease that allowed Vodafone to store telecommunications equipment on the roof.
A judge has clarified a warning he made to refer lawyers for Alvarez & Marsal to the legal watchdog after hearing of the hefty costs of complying with discovery orders won by rival EY, saying the threat wasn’t directed at counsel.
Mayfield Developments has argued the High Court should overturn a finding that NSW Ports was protected by derivative Crown immunity in entering allegedly uncompetitive agreements to privatise two ports, saying the decision could have “startling” consequences such as allowing the state to devise cartel arrangements.
A judge has allowed a class action over Isuzus that allegedly contained emissions cheat devices to send an opt out notice to group members that includes a warning that if they sell their cars, they may “lose some or all of the money” they could receive in any settlement.
Qantas has won a permanent injunction aimed at preventing unknown hackers from disseminating information accessed in a June data breach, with a judge saying the orders have “real utility” despite the hackers being beyond the reach of the court.
Baker McKenzie has appointed a new special counsel to join the law firm’s private equity practice group in its Sydney office.
Pharmaceutical giant Johnson & Johnson has denied knowingly selling alleged ineffective medications under its Benadryl, Sudafed and Codral brands, saying research indicated the phenylephrine-containing products worked.